Natalie S Dorsey, Alec E Biscopink, Brian A Houston, Jessica Atkins, Arman Kilic, Mathew Gregoski, Ryan J Tedford, Jan M Griffin
{"title":"胺碘酮与心脏移植后严重原发性移植物功能障碍和血管活性肌力评分的关系。","authors":"Natalie S Dorsey, Alec E Biscopink, Brian A Houston, Jessica Atkins, Arman Kilic, Mathew Gregoski, Ryan J Tedford, Jan M Griffin","doi":"10.1016/j.cardfail.2025.05.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The impact of amiodarone on severe primary graft dysfunction (PGD) and vasoactive inotropic scores (VISs) following heart transplantation (HT) is unclear.</p><p><strong>Methods and results: </strong>We investigated these relationships through a retrospective study of 183 consecutive patients >18 years old who underwent isolated HT at our center from 2018-2023. Data for amiodarone use in the 6 months pre-HT were recorded (duration, cumulative dosage, use at HT, last dose pre-HT). Of the 69 patients in the amiodarone cohort, 37 were considered to be taking amiodarone at the time of transplant. The primary endpoint was severe PGD, as defined by the International Society of Heart and Lung Transplantation (ISHLT) criteria. Post-HT VISs were calculated as defined by ISHLT.</p><p><strong>Conclusions: </strong>Amiodarone was not associated with severe PGD (P = 0.67), and there was no difference in post-transplant VISs based on amiodarone exposure [20 (19.6) vs 16.3 (13.8); P = 0.122] (Fig. 1). This study supports similar hemodynamic profiles post-HT, regardless of amiodarone use.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7000,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Amiodarone Association With Severe Primary Graft Dysfunction and Vasoactive Inotropic Score After Heart Transplantation.\",\"authors\":\"Natalie S Dorsey, Alec E Biscopink, Brian A Houston, Jessica Atkins, Arman Kilic, Mathew Gregoski, Ryan J Tedford, Jan M Griffin\",\"doi\":\"10.1016/j.cardfail.2025.05.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The impact of amiodarone on severe primary graft dysfunction (PGD) and vasoactive inotropic scores (VISs) following heart transplantation (HT) is unclear.</p><p><strong>Methods and results: </strong>We investigated these relationships through a retrospective study of 183 consecutive patients >18 years old who underwent isolated HT at our center from 2018-2023. Data for amiodarone use in the 6 months pre-HT were recorded (duration, cumulative dosage, use at HT, last dose pre-HT). Of the 69 patients in the amiodarone cohort, 37 were considered to be taking amiodarone at the time of transplant. The primary endpoint was severe PGD, as defined by the International Society of Heart and Lung Transplantation (ISHLT) criteria. Post-HT VISs were calculated as defined by ISHLT.</p><p><strong>Conclusions: </strong>Amiodarone was not associated with severe PGD (P = 0.67), and there was no difference in post-transplant VISs based on amiodarone exposure [20 (19.6) vs 16.3 (13.8); P = 0.122] (Fig. 1). This study supports similar hemodynamic profiles post-HT, regardless of amiodarone use.</p>\",\"PeriodicalId\":15204,\"journal\":{\"name\":\"Journal of Cardiac Failure\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.7000,\"publicationDate\":\"2025-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cardiac Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cardfail.2025.05.015\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiac Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cardfail.2025.05.015","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
Amiodarone Association With Severe Primary Graft Dysfunction and Vasoactive Inotropic Score After Heart Transplantation.
Background: The impact of amiodarone on severe primary graft dysfunction (PGD) and vasoactive inotropic scores (VISs) following heart transplantation (HT) is unclear.
Methods and results: We investigated these relationships through a retrospective study of 183 consecutive patients >18 years old who underwent isolated HT at our center from 2018-2023. Data for amiodarone use in the 6 months pre-HT were recorded (duration, cumulative dosage, use at HT, last dose pre-HT). Of the 69 patients in the amiodarone cohort, 37 were considered to be taking amiodarone at the time of transplant. The primary endpoint was severe PGD, as defined by the International Society of Heart and Lung Transplantation (ISHLT) criteria. Post-HT VISs were calculated as defined by ISHLT.
Conclusions: Amiodarone was not associated with severe PGD (P = 0.67), and there was no difference in post-transplant VISs based on amiodarone exposure [20 (19.6) vs 16.3 (13.8); P = 0.122] (Fig. 1). This study supports similar hemodynamic profiles post-HT, regardless of amiodarone use.
期刊介绍：
Journal of Cardiac Failure publishes original, peer-reviewed communications of scientific excellence and review articles on clinical research, basic human studies, animal studies, and bench research with potential clinical applications to heart failure - pathogenesis, etiology, epidemiology, pathophysiological mechanisms, assessment, prevention, and treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
